Einstein/Montefiore Department of Medicine

Grand Rounds

Vasculopathy and Disease Progression in Sickle Cell Disease

Einstein/Montefiore Department of Medicine Grand Rounds

Thursday, September 24, 2015

8:00 AM: Forchheimer Medical Science Building 3rd Floor Lecture Hall

Speaker & Info

Caterina Minniti, MD
Director, Sickle Cell Center
Division of Hematology
Departments of Medicine
Montefiore Medical Center

Repeated at 12:15 pm, Cherkasky Auditorium, Montefiore Medical Center.

Dr. Caterina Minniti is the new Director of the Sickle Cell Center of Montefiore Health Systems, in the Department of Medicine, Division of Oncology. She completed her medical education in Italy, her residency at the University of Maryland in Baltimore, and fellowships in Hematology-Oncology at Johns Hopkins University and the Pediatric Oncology Branch of the NCI. After an early career in bench research dedicated to the study of molecular genetics of soft tissue sarcomas at the Lombardi Cancer Center of Georgetown University in Washington, DC, her interest shifted to benign hematology and, specifically, hemoglobinopathies and Sickle Cell Disease. In 2000, she was selected as Director of the Red Cell Section, Children's National Medical Center in Washington, DC. In this position, she played a significant role in the execution of most of the pivotal multicenter trials in sickle cell disease, such as the STOP 2, Switch, PUSH and SiTT which led to many of the recommendations for the standard of care in prevention of SCD complications.

In 2007, Dr. Minniti joined the intramural program of NHLBI, NIH in the Pulmonary Vascular Section, currently named the Sickle Cell Branch. During that time she continued to refine and develop her expertise in designing and conducting clinical trials focused on translational research: bed to bench and back.

Dr. Minniti's research focus is on an often forgotten, and yet debilitating, complication of sickle cell disease and other hemolytic disorders, chronic leg ulcers. This is a useful model for investigating the role of progressive endothelial dysfunction, inflammation, vasculopathy, and chronic pain in end organ damage. As we approach the era when transplantation and gene therapy may be available to an increased number of individuals with sickle cell disease, risk stratification and identification of clinical and laboratory based markers of disease severity are, and will be, even more important.

Dr. Minniti holds the IND for a novel and pathogenetically based approach to the therapy of leg ulcers, topical sodium nitrite, for which she has completed a phase 1 study with promising results. Ultimately, Dr. Minniti strives to harness mechanistic insights to treat the root causes of end organ damage in SCD before it becomes irreversible.

Dr. Minniti is the author of more than 85 original articles in the field of pediatric cancers and hemoglobinopathies. She serves as an associate editor for the American Journal of Hematology, American Hematology Society annual meeting abstract reviewer, and NHLBI study sections.

Objectives - After attending this activity, participants will be able to:

  • Discuss the role of vasculopathy in the pathophysiology of sickle cell disease
  • Describe biological and clinical consequences of endothelial dysfunction in patients with sickle cell disease
  • Identify new approaches for the treatment of sickle cell disease complications

Accreditation: Albert Einstein College of Medicine designates this educational activity for a maximum of 1 credit towards the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the educational activity.

Host: Department of Medicine (Division of Hematology)

Contact Us

Department of Medicine
Albert Einstein College of Medicine
Jack and Pearl Resnick Campus
Belfer Building - Room 1008
1300 Morris Park Avenue
Bronx, NY 10461 (directions)

Physicians and Patients:
866-MED-TALK (866-633-8255)

Internal Medicine Residency Program:

Administrative Questions:
Fax: 718-430-8659

Click here to log in